CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in mea ...
Phase 2
Gilbert, Arizona, United States and 32 other locations
with histologically or cytologically confirmed stage IV colorectal cancer coming form three different patient populations:Cohort 1a: 6 patie...
Phase 1
Scottsdale, Arizona, United States and 11 other locations
and pembrolizumab) given together for the treatment of colorectal cancer that:is metastatic (spread to other parts of the body);has the cond...
Phase 2
Phoenix, Arizona, United States and 108 other locations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitr...
Phase 1
Phoenix, Arizona, United States and 32 other locations
to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer...
Phase 1, Phase 2
Scottsdale, Arizona, United States and 83 other locations
the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon...
Phase 2, Phase 3
Phoenix, Arizona, United States and 827 other locations
the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer...
Phase 1
Scottsdale, Arizona, United States and 5 other locations
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...
Phase 1
Scottsdale, Arizona, United States and 18 other locations
clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic colorectal cancer...
Phase 1
Phoenix, Arizona, United States and 8 other locations
plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treat...
Phase 3
Phoenix, Arizona, United States and 152 other locations
Clinical trials
Research sites
Resources
Legal